Peri-implantitis: early signs, prevention, and treatment

At our specialist clinic for dental implants in Zagreb, working with Swedish patients on long-term implant outcomes, the condition we spend the most prevention time on is peri-implantitis — the leading cause of late implant failure. The honest version: it is more common than many clinics admit, the early-stage form is fully reversible, and it is almost always preceded by warning signs a patient can see. The patients who know what to watch for keep their implants for decades.

Early signs — and why peri-implant mucositis is the warning before the failure

This is the most important section for patients. The transition from healthy to mucositis to peri-implantitis is not always linear — peri-implantitis often progresses in bursts, faster and more episodically than periodontitis around natural teeth. The patient who catches the warning at the mucositis stage protects the implant. The patient who waits until it hurts often loses it.

What peri-implant mucositis looks like — the early warning:

• · Gingival redness around the implant, compared to the healthy pink tissue elsewhere in your mouth
• · Bleeding when brushing or flossing near the implant — even mild bleeding is a sign
• · Slight tenderness or sensitivity around the implant gum line
• · Bad taste or mild halitosis localised to the implant
• · No pain at this stage — and that is exactly why it gets missed

What early peri-implantitis looks like — when mucositis has progressed:

• · All of the above, plus:
• · Visible gingival recession — the implant "looks longer" than before
• · Deeper pocket detectable on probing (clinical-exam finding, not a self-check)
• · Bone loss visible on bitewing X-ray (clinical finding)

Late peri-implantitis — pus discharge, pain on chewing, eventually implant mobility (rarely until very late, because implants do not loosen the way natural teeth do until bone loss is substantial).

A clinically useful nuance about bleeding. Absence of bleeding on probing at an implant has a high negative predictive value for future bone loss — implants without BoP rarely show disease progression (Monje et al. 2022). Presence of BoP alone is less specific; it must be interpreted together with probing depth and radiographs. An isolated bleeding episode is not a panic signal. Persistent bleeding plus deeper pockets is.

What we ask Swedish patients to do. Monthly self-check at home: pink, intact, non-bleeding gingiva around the implant when brushing means healthy. Anything else means book a check-up — in person at the clinic if you happen to be in the area, or with your own dentist in Sweden if not (we provide the treatment record on request).

For the biology this is the failure mode of, see our how osseointegration actually works article.

How we prevent it — and what treatment looks like if it occurs

Prevention protocol (what we do for every Swedish patient):

• · Risk profile assessment at consultation (smoking, periodontitis history, diabetes, bruxism)
• · Pre-implant periodontal treatment if natural teeth show active disease — peri-implantitis risk is markedly higher with active periodontitis
• · Implant surface selection appropriate to the risk profile (SLA / SLActive standard)
• · Screw-retained prosthetics where clinically possible to avoid cement-margin risk
• · Written home-care protocol — implant-specific interdental brushes, hygiene technique demonstration, a chlorhexidine rinse phase for the first four weeks
• · 3–6 monthly professional cleaning and radiographic monitoring — at Ars Salutaris when travel is convenient, or with the patient's own dentist in Sweden when not (we provide the necessary records on request)

Treatment if peri-implantitis occurs — staged by severity (per Berglundh 2018 framework and EFP S3 guideline, Renvert 2019):

Stage 1 — Peri-implant mucositis (no bone loss).

• · Professional cleaning around the implant
• · Improved home care
• · Chlorhexidine rinse phase (2–4 weeks)
• · Re-evaluation at 4–6 weeks
• · Fully reversible in most cases

Stage 2 — Early peri-implantitis (bone loss under 2 mm beyond baseline).

• · Non-surgical: subgingival cleaning with mechanical and air-abrasive devices, local antimicrobials, sometimes systemic antibiotics
• · Re-evaluation at 8–12 weeks
• · Honest framing per EFP S3 guideline. Non-surgical therapy at this stage is initial treatment, not generally curative for established peri-implantitis. It controls inflammation and is the right starting point. Established bone loss often requires surgical management.

Stage 3 — Moderate peri-implantitis (bone loss 2–4 mm).

• · Surgical access flap procedure
• · Implant surface decontamination (titanium curettes, glycine air-polishing)
• · Bone regenerative procedure if defect geometry permits — contained intrabony defects typically yield 2–4 mm mean probing-depth reduction and clinical attachment gain; complete defect fill is less predictable
• · Adjunctive enamel matrix derivative (EMD) in regenerative surgery — recent systematic reviews suggest ~3 mm PD reduction and 2–3 mm radiographic bone gain in selected contained defects (Ramanauskaite 2021)
• · 4–6 month healing before re-evaluation

Stage 4 — Advanced peri-implantitis (bone loss over 4 mm, mobility, or abscess).

• · Mobility implies loss of osseointegration — implant removal is indicated
• · Re-augmentation is possible after healing
• · New implant placement after 3–6 months
• · The choice between resective surgery and explantation depends on defect pattern, implant position, and prosthetic demands — not on a hard millimetre threshold alone

Adjunctive therapies with limited but real evidence. Photodynamic therapy and dental lasers offer short-term improvements in BoP and pocket depth but no consistent long-term advantage over conventional therapy. The EFP S3 guideline does not recommend them as standalone treatments for peri-implantitis. Peri-implant crevicular fluid biomarkers (IL-1β, MMP-8) and microbiome profiling are promising research tools, but they are not yet part of standard chairside diagnostic criteria.

Honest framing per voice guide §5:

We do not pretend peri-implantitis is rare. Modern longitudinal cohorts show roughly one in five patients develop peri-implantitis by 5 years and one in three by 10 years. The reversible precursor — mucositis — is even more common. The older "1–7%" figures from the early 2000s reflected looser definitions and shorter follow-up; the modern numbers are higher because the definitions are sharper, not because implants got worse. What we can promise is the prevention protocol that reduces individual risk and the early detection that keeps reversible cases reversible.

References

Sources referenced.

• Berglundh T, Armitage G, Araujo MG, et al. (2018) — Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop. J Periodontol 2018;89(Suppl 1):S313–S318. PMID 29926955. External link in H2.1.
• Derks J, Tomasi C (2015) — Peri-implant health and disease: systematic review of current epidemiology. J Clin Periodontol 2015;42(Suppl 16):S158–S171. PMID 25495683. External link in H2.3.
• Schwarz F, Derks J, Monje A, Wang H-L (2018) — Case Definitions and Diagnostic Considerations in Peri-implant Diseases. J Clin Periodontol 2018;45(Suppl 20):S278–S285. PMID 29926496. In-text (companion to Berglundh consensus).
• Renvert S, Persson GR, Pirih FQ, Camargo PM (2018) — Case definitions for peri-implant diseases. PMID 29926953. In-text.
• Renvert S, Polyzois I, et al. (2019) — EFP S3 guideline for peri-implantitis treatment. PMID 31599034. In-text.
• Chrcanovic BR et al. (2016) — smoking meta-analysis OR 2.34 (95% CI 1.92–2.85). PMID 27363721. In-text.
• Rocchietta I et al. (2015) — history of periodontitis OR 2–4× for peri-implantitis. PMID 26385005. In-text.
• Linkevicius T et al. (2013) — excess cement as peri-implantitis trigger. PMID 23458356. In-text.
• Korsch M et al. (2015) — cement-retained vs screw-retained peri-implantitis risk. PMID 25810363. In-text.
• Casado PL et al. (2013) — diabetes and peri-implant disease. PMID 24028435. In-text.
• Albrektsson T & Wennerberg A (2019) — legacy vs modern implant surfaces and peri-implantitis. PMID 30636063. In-text.
• Ramanauskaite A et al. (2021) — EMD in regenerative peri-implantitis surgery. PMID 34405392. In-text.
• Monje A et al. (2022) — Is BoP a reliable clinical indicator? J Periodontol. PMID 35166453. In-text.
• Heitz-Mayfield LJA et al. (2023) — peri-implantitis consensus (18% at 5yr / 32.7% at 10yr). In-text (also cited in post #1).
• Heitz-Mayfield LJA (2008) — Peri-implant diseases: diagnosis and risk indicators. J Clin Periodontol 2008;35(8 Suppl):292–304. Diagnostic/risk-indicator paper, NOT a prevalence systematic review (apocryphal attribution corrected 2026-05-20). In-text.